Hikma is an international pharmaceutical company conducting operations through three businesses: generic pharmaceuticals, branded pharmaceuticals and injectable pharmaceuticals. The company sells 113 branded and non-branded generic pharmaceutical products in 34 countries worldwide. The majority of Hikma's operations are in the United States, the Middle East and North Africa Region and Europe.
Hikma Pharmaceuticals Plc Ord Shs 10P is listed on the London Stock Exchange trading with ticker code HIK.L, and is part of the Medicine and Biotech Research sector. It has a market capitalisation of £411,858m, with approximately 242m shares in issue. Over the last year, Hikma Pharmaceuticals Plc share price has been traded in a range of 885, hitting a high of 2,089.00, and a low of 1,204.00.
Hikma Pharmaceuticals Plc, officially known as Hikma Pharmaceuticals Plc Ord Shs 10P was formed in September of 2005, making the company fourteen years old. The company filed its latest accounts on 31st December 2014, showing a turnover of approximately 979.15 million GBX with gross profits of 559.61 million, or 2.3160 per issued share, and a pre-tax profit margin of 24.31%. Hikma Pharmaceuticals Plc currently has 9 directors, and has had 4 previous directors over the last 14 years. In the last set of accounts produced by Deloitte Llp, the company showed 226.21 million paid in salaries to the 7,139 staff (average wage of 32 thousand), with the directors receiving an average 524 thousand each. In the accounts filed in 2014, the company paid 36167554 in dividends, or 0.1497 per share. These accounts also showed Hikma Pharmaceuticals Plc to have a net worth of 391.27 million, with 189.39 million held in cash.
Hikma Pharmaceuticals Plc is in the Medicine and Biotech Research sector.
|Evraz Plc (EVR.L)|
|Derwent London Plc (DLN.L)|
|Hutchison China Meditech Limited (HCM.L)|
|Intertek Group Plc (ITRK.L)|
|Investec Plc (INVP.L)|
|Shares in Issue||242m|
|52 Week High||2,089.00|
|52 Week Low||1,204.00|